S&P 500
7,401.00
+0.91%
Dow Jones
49,665.70
+0.19%
Nasdaq 100
29,241.00
+2.43%
Russell 2000
2,860.88
+0.82%
FTSE 100
10,263.70
+0.48%
Nikkei 225
63,767.70
+2.68%

Health and Healthcare

Dendreon Rises on Takeover Chatter (DNDN, LLY, AMGN)

Photo of Paul Ausick
By Paul Ausick Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Author
Dendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the Eli Lilly & Co. (NYSE: LLY) takeover of ImClone, which only stokes the rumor mill.

Amgen Inc. (NASDAQ: AMGN), whose bone pain drug, Xgeva, failed to get an FDA panel’s approval for use as a treatment for prostate cancer, is most often mentioned as a potential suitor for Dendreon. Dendreon’s market cap of around $1.5 billion is well within Amgen’s scope.

Dendreon’s shares are up more than 4.5% at $10.39 in a 52-week range of $6.46-$43.96.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Paul Ausick |

Dendreon Shares Still Rising (DNDN)

Shares of Dendreon Corp. (NASDAQ: DNDN) rose nearly 50% yesterday following an announcement that sales of the company’s prostate cancer…

Douglas A. McIntyre |

Short Sellers Help Push Dendreon Higher

Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that…

Jon C. Ogg |

Total Curve Ball for Prostate Cancer Field (DNDN, JNJ, MDVN)

Dendreon Corporation (NASDAQ: DNDN) may be losing its favor as the prostate cancer drug of choice.  That is at least…

Jon C. Ogg |

The Questionable Dendreon Buyout Incentive

Dendreon Corp. (NASDAQ: DNDN) is by almost all measurements nothing short of a total failure of a biotech or biohealth…

Douglas A. McIntyre |

Comment From The Stock Masters

All eyes are on Dendreon Corporation (DNDN) today and their shares have been halted ahead of their meeting with the…

Jon C. Ogg |

Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN)

Medivation, Inc. (NASDAQ: MDVN) is today’s darling in biotech and emerging pharmaceuticals.  It and partner Astellas in Japan showed very…

Jon C. Ogg |

Dendreon In Trouble

AuthorDendreon Corporation (NASDAQ: DNDN) is in trouble.  That is what the performance is telling investors.  The maker of Provenge as…

David J. Phillips |

Dendreon: Not Running Out Of Cash

In the last four months, Dendreon Corp. (DNDN) has shed almost 84 percent in market value as disgruntled investors washed…

Douglas A. McIntyre |

A Make or Break Week for Dendreon (DNDN)

Dendreon(DNDN-NASDAQ) is going to be one of "THE TOP ISSUES" this week.  The company will have and FDA review panel…

Top Gaining Stocks

Akamai
AKAM • Vol: 21,556,944
Micron Technology
MU • Vol: 65,135,624
Intel
INTC • Vol: 227,504,426
Monster Beverage
MNST • Vol: 15,284,847
Dell Technologies
DELL • Vol: 12,167,525

Top Losing Stocks

Mettler Toledo International
MTD • Vol: 539,266
Motorola Solutions
MSI • Vol: 3,101,643
Expedia
EXPE • Vol: 4,189,786
Coterra Energy
CTRA • Vol: 73,319,495
Fidelity National Information Services
FIS • Vol: 11,468,820